Metropolitan Life Insurance Company (MetLife)’s Aimmune Therapeutics AIMT Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2020
Q4 | – | Sell |
-14,177
| Closed | -$488K | – | 2608 |
|
|
2020
Q3 | $488K | Hold |
14,177
| – | – | 0.01% | 1231 |
|
|
2020
Q2 | $237K | Hold |
14,177
| – | – | ﹤0.01% | 1692 |
|
|
2020
Q1 | $204K | Sell |
14,177
-192
| -1% | -$4.91K | ﹤0.01% | 1576 |
|
|
2019
Q4 | $481K | Hold |
14,369
| – | – | 0.01% | 1350 |
|
|
2019
Q3 | $301K | Hold |
14,369
| – | – | 0.01% | 1609 |
|
|
2019
Q2 | $299K | Hold |
14,369
| – | – | 0.01% | 1622 |
|
|
2019
Q1 | $321K | Hold |
14,369
| – | – | 0.01% | 1586 |
|
|
2018
Q4 | $344K | Hold |
14,369
| – | – | 0.01% | 1464 |
|
|
2018
Q3 | $392K | Hold |
14,369
| – | – | 0.01% | 1536 |
|
|
2018
Q2 | $386K | Buy |
14,369
+2,501
| +21% | +$76.5K | 0.01% | 1497 |
|
|
2018
Q1 | $378K | Buy |
11,868
+241
| +2% | +$8.48K | 0.01% | 1463 |
|
|
2017
Q4 | $440K | Sell |
11,627
-13,146
| -53% | -$424K | 0.01% | 1373 |
|
|
2017
Q3 | $614K | Hold |
24,773
| – | – | ﹤0.01% | 1551 |
|
|
2017
Q2 | $509K | Buy |
24,773
+5,372
| +28% | +$102K | ﹤0.01% | 1677 |
|
|
2017
Q1 | $422K | Sell |
19,401
-1,395
| -7% | -$28.6K | ﹤0.01% | 1764 |
|
|
2016
Q4 | $425K | Hold |
20,796
| – | – | ﹤0.01% | 1853 |
|
|
2016
Q3 | $312K | Hold |
20,796
| – | – | ﹤0.01% | 2039 |
|
|
2016
Q2 | $225K | Buy |
20,796
+11,179
| +116% | +$152K | ﹤0.01% | 2244 |
|
|
2016
Q1 | $130K | Buy |
9,617
+797
| +9% | +$12.4K | ﹤0.01% | 2392 |
|
|
2015
Q4 | $163K | Buy |
+8,820
| New | +$163K | ﹤0.01% | 2388 |
|
Metropolitan Life Insurance Company (MetLife)'s AIMT Position: Q4 2020 in Review
Metropolitan Life Insurance Company (MetLife) sold out of Aimmune Therapeutics (AIMT) in Q4 2020, closing a stake of 14,177 shares — an estimated $488K sold.
Metropolitan Life Insurance Company (MetLife) first reported a position in AIMT in Q4 2015 and held it in 20 quarters. The position peaked at $614K in Q3 2017. 0 funds tracked by Wall St. Rank hold AIMT as of Q4 2020.
- Metropolitan Life Insurance Company (MetLife) reported no remaining Aimmune Therapeutics position as of Q4 2020 after selling out during the quarter.
- Metropolitan Life Insurance Company (MetLife) sold 14,177 Aimmune Therapeutics shares in Q4 2020, an estimated $488K.
- Metropolitan Life Insurance Company (MetLife) first reported a position in Aimmune Therapeutics in Q4 2015 and held it in 20 quarters.
- Metropolitan Life Insurance Company (MetLife)'s Aimmune Therapeutics position peaked at $614K in Q3 2017.
- 0 funds tracked by Wall St. Rank held Aimmune Therapeutics as of Q4 2020.
Based on Metropolitan Life Insurance Company (MetLife)'s 13F filing for Q4 2020, filed 16 Feb 2021.